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Introduction
Chronic anterior uveitis is a common complication of
juvenile idiopathic arthritis (JIA). Leflunomide is a fre-
quently used alternative to methotrexate in the treat-
ment of joint manifestations of JIA. However, very little
is known on the effect of leflunomide treatment on con-
current chronic uveitis in JIA.
Objectives
To investigate patients with juvenile idiopathic arthritis
with a history of non-simultaneous treatment of metho-
trexate and leflunomide, and to compare flare rates of
uveitis during treatment periods with both drugs in
these patients.
Methods
The database of the German Center for Pediatric and
Adolescent Rheumatology was searched for all patients
admitted from January 2010 until October 2011 with a
diagnosis of juvenile idiopathic arthritis and chronic
anterior uveitis and treatment periods with both lefluno-
mide and methotrexate. Patients with uveitis due to
other causes were excluded. A retrospective chart survey
was used to extract demographic data, diagnosis, and
start and end times of treatment with leflunomide and
methotrexate, respectively, concomitant medications and
numbers of anterior uveitis flares. Anterior uveitis flare
was defined as detection of any anterior chamber cells
or flares after previously documented inactivity by an
ophthalmologist. A generalized linear mixed model was
constructed using a negative binomial distribution.
Number of flares was used as the dependent variable,
and the two treatments, LFN and MTX, were consid-
ered repeated measurements. The logarithm of time was
used as an offset variable.
Results
15 patients were included in the study, 9 patients
with extended oligoarthritis, three with seronegative
polyarthritis, two with persistent oligoarthritis and one
with psoriatic arthritis. 100% had positive antinuclear
antibodies. All patients were treated with methotrexate
prior to leflunomide treatment, six patients had a sec-
ond course of methotrexate and one patient a second
course of leflunomide. 10 patients showed uveitis prior
to treatment, and five patients developed uveitis
on treatment with methotrexate. Median time of treat-
ment with methotrexate was 51 months (range 26 - 167
months), and with leflunomide was 12 months (range
4 - 47 months). While on methotrexate, one patients
each received etanercept and adalimumab, and one sub-
sequent courses of both, compared to five patients on
adalimumab and one each on etanercept and on inflixi-
mab while on leflunomide. On 1012 months of metho-
trexate treatment, 25 flares occurred, while on 247
months of leflunomide treatment, 15 flares occurred.
This corresponds to a flare rate of 0.0247 flares/month
on methotrexate treatment and 0.0607 flares/month on
leflunomide treatment (p = 0.008).
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Conclusion
Despite more co-medications potentially improving the
uveitis outcome in leflunomide treatment periods,
patients showed significantly more flares of uveitis com-
pared to treatment periods with methotrexate. Further
research is necessary to assess leflunomide efficacy in
chronic uveitis associated with JIA.
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